554 related articles for article (PubMed ID: 29026920)
1. Immunotherapy as an Option for Cancer Treatment.
Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
[TBL] [Abstract][Full Text] [Related]
2. An overview of cancer immunotherapeutic strategies.
Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of cancers comes of age.
Yousefi H; Yuan J; Keshavarz-Fathi M; Murphy JF; Rezaei N
Expert Rev Clin Immunol; 2017 Oct; 13(10):1001-1015. PubMed ID: 28795649
[TBL] [Abstract][Full Text] [Related]
4. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
Overwijk WW
Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of colorectal cancer: new perspectives after a long path.
Correale P; Botta C; Ciliberto D; Pastina P; Ingargiola R; Zappavigna S; Tassone P; Pirtoli L; Caraglia M; Tagliaferri P
Immunotherapy; 2016 Nov; 8(11):1281-1292. PubMed ID: 27993089
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy: the beginning of the end of cancer?
Farkona S; Diamandis EP; Blasutig IM
BMC Med; 2016 May; 14():73. PubMed ID: 27151159
[TBL] [Abstract][Full Text] [Related]
8. Progress and opportunities for immune therapeutics in osteosarcoma.
Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms.
Sun L; Chen L; Li H
Int Immunopharmacol; 2019 Feb; 67():160-175. PubMed ID: 30553199
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapies: Exploiting the Immune System for Cancer Treatment.
Koury J; Lucero M; Cato C; Chang L; Geiger J; Henry D; Hernandez J; Hung F; Kaur P; Teskey G; Tran A
J Immunol Res; 2018; 2018():9585614. PubMed ID: 29725606
[TBL] [Abstract][Full Text] [Related]
11. The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy.
Zhao H; Li Y; Wei D; Luo H
J Immunol Res; 2018; 2018():3673295. PubMed ID: 30406152
[TBL] [Abstract][Full Text] [Related]
12. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy.
Cannon MJ; Block MS; Morehead LC; Knutson KL
Immunotherapy; 2019 Feb; 11(2):75-79. PubMed ID: 30730268
[No Abstract] [Full Text] [Related]
13. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
Fecek RJ; Storkus WJ
Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
[TBL] [Abstract][Full Text] [Related]
14. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
Grenier JM; Yeung ST; Khanna KM
Front Immunol; 2018; 9():610. PubMed ID: 29623082
[TBL] [Abstract][Full Text] [Related]
15. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
16. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
17. Adapting Cancer Immunotherapy Models for the Real World.
Klevorn LE; Teague RM
Trends Immunol; 2016 Jun; 37(6):354-363. PubMed ID: 27105824
[TBL] [Abstract][Full Text] [Related]
18. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
Versteven M; Van den Bergh JMJ; Marcq E; Smits ELJ; Van Tendeloo VFI; Hobo W; Lion E
Front Immunol; 2018; 9():394. PubMed ID: 29599770
[TBL] [Abstract][Full Text] [Related]
19. Novel vaccines for glioblastoma: clinical update and perspective.
Winograd EK; Ciesielski MJ; Fenstermaker RA
Immunotherapy; 2016 Nov; 8(11):1293-1308. PubMed ID: 27993092
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
